# AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC

> **NCT06472037** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Locally Advanced Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Cadonilimab
- **DRUG:** Gemcitabine
- **DRUG:** Nab-Paclitaxel

## Key facts

- **NCT ID:** NCT06472037
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06472037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06472037, "AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06472037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*